Journal article
Adverse event reporting for cellular therapy products: Current status and future directions.
- Loper K Center for Cellular Therapies, AABB, Bethesda, Maryland, USA.
- Sugrue MW Division of Hematology/Oncology, Department of Medicine, University of Florida, Gainesville, Florida, USA.
- Raval JS Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA.
- Schwartz JY Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA.
- Land K Vitalant, Phoenix, Arkansas, USA.
- Koh M St George's Hospital and Medical School, London, UK.
- Mengling T DKMS Gemeinnützige GmbH, Tübingen, Germany.
- Greinix H Division of Hematology, Medical University Graz, Graz, Austria.
- Halter JP Hematology, University Hospital Basel, Basel, Switzerland.
- Celluzzi CM Center for Cellular Therapies, AABB, Bethesda, Maryland, USA.
- Chaudhri M Center for Cellular Therapies, AABB, Bethesda, Maryland, USA.
- 2020-10-16
Published in:
- Transfusion. - 2020
English
Adverse event (AE) and adverse reaction (AR) reporting are key components of patient safety and surveillance systems. Review and analysis of this data yields opportunities for process improvement, product information and interventions, and can lead to improved patient outcomes and donor safety overall. AE and AR reporting for cellular therapy products is fragmented and not well characterized in a central reference. This review article, authored by experts from various organizations, serves to summarize the current state of reporting and offers opportunities for streamlining and coordination, as well as key reference for professionals in this field.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1111/trf.16062
- PMID 33063875
- Persistent URL
- https://sonar.ch/global/documents/231848
Statistics
Document views: 32
File downloads: